News|Articles|March 10, 2017

Global Regulators Collaborate to Improve Access to Safe Drugs

Author(s)Pharmaceutical Technology Editors

The European Medicines Agency met with European and African regulators to discuss how to improve the availability of safe and effective drugs beyond Europe.

The European Medicines Agency met with regulators from the European Union and Africa in a workshop held in Malta from March 2-3, 2017 to discuss how the different agencies can work together to improve the availability safe and effective drugs to areas outside of Europe. The workshop was organized by EMA and the Maltese Presidency of the European Union with the support of the Bill & Melinda Gates Foundation and the World Health Organization (WHO).

Workshop attendees discussed how EMA could conduct scientific assessment of drugs or vaccines for use outside of the EU in line with European legislation and in cooperation with WHO. These assessments could increase access to safe medications to patients in low- and middle-income countries.

“Effective medicine regulation plays a crucial role in every health system to ensure that all medicines are safe, effective and meet approved standards,” said EMA Executive Director Guido Rasi, in a press release. “I am confident that by increasing our two-way dialogue and the information on regulatory tools available we can strengthen international collaboration and benefit patients.”

Source: EMA

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

Ravulizumab gains FDA accelerated approval for IgA nephropathy after it cut proteinuria by 43.4%.

October 22nd, 2026

Ravulizumab's IgA Nephropathy Approval Expands Large-Molecule Biologic Demand

FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.

FDA approves GSK’s bepirovirsen for hepatitis B, putting antisense oligonucleotide scale-up in focus.

October 21st, 2026

FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note

FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

October 20th, 2026

Drug-Device Combination Apps: The FDA's 3 Questions for Sponsors

FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.

October 19th, 2026

Expedited IND Pilot Targets Sequential Delays Slowing First-in-Human Trials

Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com

October 9th, 2026

Power of Two One-Sided Tests with Unequal Variances

Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.

October 22nd, 2026

Ask the Expert: Choosing Ingredient Suppliers

Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.